Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | CLK2 | P49760 | 1/20 | 0.71 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.71 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.71 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130215 | 0.92 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5130959 | 0.91 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5121159 | 0.91 | PARP1 (1.00) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL5131324 | 0.89 | PARP1 (1.00) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL5131128 | 0.88 | PARP1 (1.00) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL5131354 | 0.87 | PARP1 (1.00) | PARP1 | |
| SCHEMBL2763260 | 0.87 | PARP1 (0.79) | PARP1 | |
| SCHEMBL5127094 | 0.85 | PARP1 (1.00) | PARP1MAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL5130793 | 0.85 | PARP1 (1.00) | PARP1 | |
| SCHEMBL5126905 | 0.85 | PARP1 (1.00) | PARP1MAP4K4CLK2MAP4K2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | claimed |
| US-9283222-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8466150-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2013-06-18 | — | — | US | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | PARP1 1/4885MAP4K4 1403/4885CLK2 2798/4885 |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | PARP1 1/4885MAP4K4 3915/4885CLK2 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.